E
Eric Billaud
Researcher at French Institute of Health and Medical Research
Publications - 98
Citations - 2035
Eric Billaud is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 22, co-authored 81 publications receiving 1803 citations. Previous affiliations of Eric Billaud include Hotel Dieu Hospital & University of Nantes.
Papers
More filters
Journal ArticleDOI
Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma
François Boué,Jean Gabarre,Christian Gisselbrecht,Jacques Reynes,Antoine Cheret,Fabrice Bonnet,Eric Billaud,Martine Raphael,Rémi Lancar,Dominique Costagliola +9 more
TL;DR: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
Journal ArticleDOI
Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms.
Dominique Emilie,John Wijdenes,Christian Gisselbrecht,B Jarrousse,Eric Billaud,Jean-Yves Blay,Gabarre J,J P Gaillard,Jean Brochier,Martine Raphael +9 more
TL;DR: The results indicate that in some cases of lymphomas growth of malignant cells may be partially IL- 6-dependent and that neutralizing endogenous effect of IL-6 completely abrogates B clinical symptoms.
Journal ArticleDOI
Detection of Microsporidia and Identification of Enterocytozoon bieneusi in Surface Water by Filtration Followed by Specific PCR.
Jean Marc Sperfel,Claudine Sarfati,Olivier Liguory,Bruno Caroff,Nadine Dumoutier,Brigitte Gueglio,Eric Billaud,François Raffi,Jean-Michel Molina,Michel Miegeville,Francis Derouin +10 more
TL;DR: The development of a filtration and PCR-based method for detection of microsporidial spores and the presence of E. bieneusi in one sample of surface water from the river Seine is demonstrated.
Journal ArticleDOI
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Stanislas Pol,Marc Bourlière,Sandy Lucier,Christophe Hézode,Céline Dorival,Dominique Larrey,Jean-Pierre Bronowicki,Victor de Ledinghen,Fabien Zoulim,Albert Tran,Sophie Metivier,Jean-Pierre Zarski,Didier Samuel,Dominique Guyader,Patrick Marcellin,Anne Minello,Laurent Alric,Dominique Thabut,Olivier Chazouillères,Ghassan Riachi,Valérie Bourcier,Philippe Mathurin,Véronique Loustaud-Ratti,Louis d’Alteroche,Isabelle Fouchard-Hubert,François Habersetzer,Xavier Causse,Claire Geist,Isabelle Rosa,Jérôme Gournay,Eric Saillard,Eric Billaud,Ventzislava Petrov-Sanchez,Alpha Diallo,Hélène Fontaine,Fabrice Carrat +35 more
TL;DR: The sofosbuvir+daclatasvir combination of antiviral drugs is associated with a high rate of SVR12 in patients infected by genotype 1, with an optimal duration of 12weeks in non-cirrhotic patients and 24weeks for those with cirrhosis.
Journal ArticleDOI
Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.
Jean-Michel Tassie,Jacques Gasnault,Michèle Bentata,Jacqueline Deloumeaux,François Boué,Eric Billaud,Dominique Costagliola +6 more
TL;DR: This study of a large cohort of patients diagnosed with PML provides evidence that a combination antiretroviral regimen, especially one including PI, confers marked survival benefits.